Daily Stock List
RenovaCare, Inc. (RCAR)
Today we are highlighting RenovaCare, Inc. (RCAR), here at the QualityStocks Daily Newsletter.
RenovaCare, Inc. is developing first-of-their-kind autologous (self-donated) stem cell therapies for the regeneration of human organs. Its initial product under development targets the body’s largest organ, the skin. RenovaCare is the developer of the patented CellMist™ and SkinGun™ technologies. These are for isolating and spraying a patient’s own stem cells onto burns and wounds for rapid self-healing. RenovaCare is headquartered in New York City.
The Company’s flagship technology, the CellMist™ System, uses its patented SkinGun™ to spray a liquid suspension of a patient’s stem cells – the CellMist™ Solution – onto wounds. RenovaCare is developing its CellMist™ System as a promising new option for patients suffering from burns, chronic and acute wounds, and also scars. The Company’s CellMist™ System targets an estimated 143 million patients around the world who suffer burns, chronic and acute wounds, acne scarring, and skin defects and diseases such as vitiligo.
In investigative clinical use in the U.S., SkinGun™ treatments have shown the potential to naturally and quickly heal burns and other serious wounds. Based on preliminary case studies, CellMist™ System patients can be treated within 90 minutes of entering in an emergency room. A patient’s stem cells are isolated, processed, and sprayed on to wound sites for quick healing.
RenovaCare has a partnership to validate the science behind its ground-breaking technology for treatments of wounds, burns and other skin defects. The Company’s research partner is Berlin-Brandenburg Center for Regenerative Therapies (BCRT), a translational research center at Charité - Universitätsmedizin Berlin, one of the world’s largest university hospitals.
The BCRT focuses on enhancing endogenous regeneration by cells, biomaterials, and factors that can be used to develop and implement pioneering therapies and products. Charité - Universitätsmedizin Berlin covers four campuses and comprises roughly 100 Departments and Institutes.
This week, RenovaCare announced the appointment of Mr. Steven Q. Wang to its Board of Advisors. Dr. Wang is Head of Dermatology Section and Director of Dermatologic Surgery and Dermatology at Memorial Sloan-Kettering Cancer Center in Basking Ridge, New Jersey. He specializes in the diagnosis, treatment, and prevention of skin cancers, particularly melanoma. Dr. Wang’s research has been centered on melanoma detection, nanotechnologies, photoprotection, drug delivery and medical informatics.
RenovaCare, Inc. (RCAR), closed Thursday's trading session at $1.74, up 7.97%, on 23,730 volume with 30 trades. The average volume for the last 60 days is 10,069 and the stock's 52-week low/high is $0.80/$2.26.
Natcore Technology, Inc. (NTCXF)
Vantage Wire reported previously on Natcore Technology, Inc. (NTCXF), and today we report on the Company, here at the QualityStocks Daily Newsletter.
Natcore Technology, Inc. focuses on using its proprietary nanotechnology discoveries to enable an assortment of compelling applications in the solar industry. The Company is advancing applications in laser processing, black silicon, and quantum-dot solar cells. This is to considerably lower the costs and improve the power output of solar cells. Natcore Technology is based in Rochester, New York.
The Company does not manufacture solar cells. It controls technology that it believes will make solar energy cost-competitive with energy derived from fossil fuels. Natcore Technology has established exclusive licenses and/or joint research agreements with Rice University, the National Renewable Energy Laboratory, and the University of Virginia.
Natcore, using its liquid phase deposition, black silicon, and laser technology, grows a thin anti-reflective coating on a silicon disc without the necessity for toxic chemicals or a high-temperature vacuum furnace. The Company is replacing the traditional thermal vacuum processes, including CVD and PECVD (chemical vapor deposition, plasma enhanced chemical vapor deposition, and more) for making solar cells with its liquid phase deposition (LPD) wet chemistry process. LPD is at the core of everything Natcore Technology does.
The Company has developed a solar cell that eliminates the use of silver. The Company announced the development of a ground-breaking solar cell structure on July 9, 2015. It indicated that the new low-cost configuration may allow for the elimination of silver from mass-produced solar cells. It said that now, this long-time goal of solar scientists has been attained. Natcore Technology scientists have built an all-back-contact silicon heterojunction cell structure; silver has been totally eliminated. It has been replaced by aluminum. The substitution has been accomplished with no loss of performance. Silver represents over 48 percent of the metallization cost of a solar cell, or around 11 percent of the total raw material cost of a solar module.
Natcore Technology is the exclusive licensee, from Rice University, of a new thin-film growth technology. The Company says that its technology has two immediate and compelling applications in the solar segment. It could enable silicon solar cell manufacturers to reduce silicon usage by more than 60 percent. Moreover, Natcore says that it promises to allow, for the first time, mass manufacturing of super-efficient (30 percent +) tandem solar cells with double the power output of today’s most efficient devices.
This month, Natcore Technology announced that it completed the third and final tranche of its proposed non-brokered private placement (announced on November 26, 2015). Gross proceeds of $98,300.88 were raised via the sale of 273,058 units at a price of $0.36 per unit. Each unit consisted of one common share and one share purchase warrant. Each warrant entitles the holder to purchase of a further common share at $0.55 for a period of three years.
Natcore Technology, Inc. (NTCXF), closed Thursday's trading session at $0.365, down 1.35%, on 43,575 volume with 16 trades. The average volume for the last 60 days is 54,419 and the stock's 52-week low/high is $0.2258/$0.7089.
Biotech Products Services & Research, Inc. (BPSR)
Today we choose to report on Biotech Products Services & Research, Inc. (BPSR), here at the QualityStocks Daily Newsletter.
Listed on the OTC Bulletin Board and founded in 2011, Biotech Products Services & Research, Inc. concentrates on a lifestyle of health and wellness. The Company’s vision is to be a vertically integrated enterprise that mainly provides a patient referral service for integrative cellular therapies. In addition, Biotech also markets cellular products to doctors and hospitals. The Company has its corporate headquarters in Bay Harbor Islands, Florida.
Biotech Products Services & Research (BPSR) is a patient referral, product development, and research entity. It specializes in the discovery, development and dispatch of cellular therapies for treating neurodegenerative, inflammatory and autoimmune conditions for patients globally.
The Company’s emphasis is on disease management. It maintains a network of physicians in the U.S. and elsewhere who have all been trained completely in its methods. BPSR has a number of patents pending, which make use of the aforementioned cellular products for anti-aging, regeneration and cosmetics. BPSR has a patient referral network that permits patients to be treated for diverse medical conditions within the Company’s own network of doctors.
BPSR’s commitment is to the study and development of autologous cellular therapies, which will treat many degenerative diseases, and also advancing its present research into the treatment of neurological, cardiovascular and peripheral vascular diseases.
Recently, BPSR announced a commercial referral agreement was signed with US Stem Cell Clinic (Sunrise, Florida) and BPSR’s wholly-owned subsidiary "Beyond Cells LLC". The new working relationship will extend considerable benefits to Beyond Cells’ clients looking for effective alternative therapies. The Company’s clientele will now have a direct pathway to the conveniently located US Stem Cell Clinic in southern Florida for adipose stem cell and other advanced regenerative therapy treatments.
Last month, BPSR announced the launch of its wholly-owned subsidiary, General Surgical Florida, Inc. It stated that the team at General Surgical will work towards establishing sales distribution channels of regenerative products to hospitals, physicians, and also third party distributors. General Surgical will be providing access to advanced regenerative medical technologies. This includes adipocyte, bone marrow and placental regenerative tissues. It will also be expanding education services to providers in BPSR's referral network.
Biotech Products Services & Research, Inc. (BPSR), closed Thursday's trading session at $0.58, up 5.45%, on 103,584 volume with 58 trades. The average volume for the last 60 days is 5,135 and the stock's 52-week low/high is $0.45/$8.75.
Spotlight Innovation, Inc. (STLT)
Ceocast News reported yesterday on Spotlight Innovation, Inc. (STLT), TopPennyStockMovers and Real Pennies did previously, and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.
OTCQB-listed Spotlight Innovation, Inc. identifies and acquires rights to innovative and proprietary platform technology candidates. The Company’s focus is on cancer drugs and related treatment therapies, solutions for infectious disease, and other specialty and unique opportunities. Headquartered in West Des Moines, Iowa, Spotlight Innovation provides solutions for healthcare-focused companies commercializing healthcare intellectual property (IP).
The Company’s corporate mission is to meaningfully impact patient health by advancing new platform biotechnologies for cancer and infectious disease. Access to platform technology candidates is achieved through its wide-ranging relationships with numerous leading academic institutions and other sources.
Spotlight Innovation provides value-added development capability and funding to hasten development progress. The Company will partner with proven market leaders by way of sale, out-license or strategic alliance, when commercially significant benchmarks have been attained.
Spotlight Innovation works to acquire the rights, through acquisition, license or otherwise, to unique and proprietary Platform Technology Candidates. It also works to provide value-added development capability and funding to realize rapid IND approval to start human clinicals for targeted Platform Technology Candidates.
Furthermore, it works to commercialize, for each Platform Technology Candidate, one or multiple indications through sale, out-license, or strategic relationships/marketing agreements. This is while continuing to retain, where practical, rights/”fields of use” to other indications for future commercialization.
In January, Spotlight Innovation announced that it retained distinguished French oncologist Mr. David Khayat, MD, PhD, FASCO, as the Principal Investigator for a European Phase I dose escalation safety study, Crotoxin in Patients with Advanced Cancer using an Intravenous Route of Administration. The clinical study will take place at Pitié-Salpêtrière Hospital in Paris, France. Prof. Khayat leads the Department of Medical Oncology at Pitié-Salpêtrière Hospital. He is a Board Member of the American Society of Clinical Oncology (ASCO).
Crotoxin is one of several proprietary compounds, owned by Spotlight Innovation, derived from snake venom. These compounds possess specific anti-cancer and analgesic properties that apply to a wide array of treatments for solid cancerous tumors and pain management. Spotlight Innovation said that of particular significance, these compounds create minimal side effects.
Spotlight Innovation, Inc. (STLT), closed Thursday's trading session at $0.64, up 3.23%, on 9,000 volume with 6 trades. The average volume for the last 60 days is 2,020 and the stock's 52-week low/high is $0.51/$1.73.
Inventergy Global, Inc. (INVT)
BUYINS.NET, OTCBB Journal, Broad Street, First Penny Picks, StocksImpossible, and Jason Bond reported recently on Inventergy Global, Inc. (INVT), here at the QualityStocks Daily Newsletter.
Inventergy Global, Inc. is a Silicon Valley intellectual property (IP) company. The Company’s commitment is to identifying, acquiring and licensing patented technologies of market-significant technology leaders. IP industry pioneer and veteran, Mr. Joe Beyers, leads Campbell, California-based Inventergy Global. He is well-known and highly regarded throughout the IP world for his accomplishments at Hewlett-Packard. The Company’s shares trade on the Nasdaq Capital Market (NasdaqCM).
Inventergy Global takes advantage of decades of corporate experience, market and technology expertise, and industry connections to help Fortune 500 companies in leveraging the value of their innovations to realize greater returns. Inventergy Global has expertise in every aspect of IP business. This is from valuation to technical and legal analyses to successful deal making.
In essence, the Company is primarily an investment and licensing company. It is strategically centered on partnering with technology leaders.
Inventergy Global structures an IP licensing and value creation strategy for a client’s particular assets; applies decades of IP and business expertise and best practices;
takes advantage of important industry relationships to start with the right decision makers at potential licensees; accesses best-of-breed industry resources; integrates technology and market expertise to determine fair value; and takes a business approach to IP licensing, which reflects a client’s corporate brand and values.
In January, Inventergy Global announced that it entered into a definitive agreement with institutional investors for the private placement of shares of convertible preferred stock and warrants to purchase shares of common stock for gross proceeds of roughly $2.5 million. The Company’s intention is to use the net proceeds of the transaction for working capital and payment of existing obligations.
Mr. Joe Beyers, Chief Executive Officer of Inventergy Global, said, "This financing represents a major milestone for Inventergy and we are extremely thankful for the support of our new and existing investors. We believe this investment helps propel our corporate trajectory towards what we view as a strong pipeline of potential revenue. It provides us with resources to execute on this pipeline and to enhance shareholder value."
Inventergy Global, Inc. (INVT), closed Thursday's trading session at $2.22, up 6.73%, on 248,155 volume with 732 trades. The average volume for the last 60 days is 847,369 and the stock's 52-week low/high is $0.71/$9.40.
Nutra Pharma Corp. (NPHC)
The QualityStocks Daily Newsletter would like to spotlight Nutra Pharma Corp. (NPHC). Today, On the Move Systems, Inc. closed trading at $0.041, up 51.85%, on 2,174,157 volume with 104 trades. The stock’s average daily volume over the past 60 days is 375,633, and its 52-week low/high is $0.0025/$0.27.
Nutra Pharma Corp. (NPHC) is a biotech company working in collaboration with its subsidiaries to develop an innovative pipeline of biopharmaceutical products for the management of neurological disorders, cancer, autoimmune, and infectious diseases. At the core of Nutra Pharma's intellectual property is a unique platform for extracting neurotoxins from Asian cobra venom and transforming them into non-toxic therapeutics.
The ReceptoPharm subsidiary, Nutra Pharm's drug discovery arm, is focused on the development of new therapeutic agents based upon specialized receptor-binding proteins found in nature, especially those found in snake venom from the cobra. ReceptoPharm's R&D pipeline consists of several novel therapies in various stages of development to prevent and/or treat multiple sclerosis (MS), human immunodeficiency virus (HIV), adrenomyeloneuropathy (AMN), herpes, rheumatoid arthritis (RA) and pain. The subsidiary also provides small and start-up biotech companies a full range of contract research services through its ISO class 5 and GMP certified facilities in Plantation, Florida.
Nutra Pharma recently received Orphan Drug Status from the FDA for the treatment of pediatric MS for its drug, RPI-78M. The designation of RPI-78M as an Orphan Drug provides Nutra Pharma with a seven-year period of market exclusivity in the U.S. once the drug is approved. Additional benefits over conventional drug applications include: tax credits for clinical research costs, the ability to apply for grant funding, clinical trial design assistance, plus assistance from the FDA in the drug development process and the waiver of Prescription Drug User Fee Act (PDUFA) filing fees which could be in excess of $2.5 million. The granting of Orphan Drug Designation allows Nutra Pharma to move forward with its preparation of an Investigative New Drug Application and proposal of clinical trials. The FDA grants Orphan Drug Designation status to products that treat rare diseases, providing incentives to sponsors developing drugs or biologics.
ReceptoPharm holds all of the intellectual property for Nutra Pharma's drug pipeline, while Nutra Pharma directly holds all of the property dealing with their over-the-counter drugs. This includes Nyloxin, an OTC pain reliever for humans, and Pet Pain-Away, a pain reliever for dogs and cats. The company's Nyloxin product is the first OTC pain reliever clinically proven to treat moderate to severe chronic pain. The drug is available as an oral spray for treating lower back pain, migraines, neck aches, shoulder pain, cramps and neuralgia and as a topical gel for treating joint pain and pain associated with repetitive stress and arthritis.
Nutra Pharma is a revenue-generating company with 12 patents and patents pending, three completed phase 1/phase 2 clinical trials, and 12 FDA-registered OTC products in the United States. The company also has regulatory clearance for Nyloxin in India, where management believes its initial distribution streams could become the company's biggest market. Management is also defining its plan to expand into China and Canada while strengthening its position the United States. Disclaimer
Nutra Pharma Corp. Company Blog
Nutra Pharma Corp. News:
Nutra Pharma Corp.ís (NPHC) 7-year Marketing Exclusivity for Pediatric MS RPI-78M is more than just Luck
Nutra Pharma Letter to Shareholders
Nutra Pharma Corp. (NPHC) CEO Featured in Exclusive QualityStocks Interview
Star Mountain Resources, Inc. (SMRS)
The QualityStocks Daily Newsletter would like to spotlight Star Mountain Resources, Inc. (SMRS). Today, Star Mountain Resources, Inc. closed trading at $0.589, up 9.07%, on 2,000 volume with 3 trades. The stock’s average daily volume over the past 60 days is 8,403, and its 52-week low/high is $0.40/$1.40.
Star Mountain Resources, Inc. (SMRS), a minerals exploration company, is focused on acquiring and consolidating mining claims, mineral leases, producing mines, and historic mines with production and future growth potential identified through exploration efforts. The company's operations are currently focused on the initiation, production and expansion of acquired mineral resources in the Star Mountain Mining District, Beaver County, Utah and turning them into producing assets.
Comprised of 2,320 acres, the company's Star Mountain/Chopar Mine project consists of 116 lode-mining claims and four metalliferous mineral lease sections located in the Star Mountain range, Star Mining District, in Beaver County, Utah, approximately five miles west of Milford, Utah. Exploration activities to date include geological analysis, and a limited reverse circulation & core drilling program.
The Star Mountain Mining District, which is dotted with historic mines dating back to the late 1800s, has a long and storied history within the mining industry. The company believes that the application of modern exploration tools will reveal additional resources that were previously unattainable. Leveraging the region's mild climate and accessibility to nearby rail lines and roads, management will look to translate this potential into sustainable returns in the years to come.
Star Mountain Resources has adopted a discovery-based business model to grow its industry presence in the future. The company plans to thoroughly explore and initially develop its leasehold before seeking senior industry partners to assist in the capital-intensive development and operation phases. Building on this strategy, Star Mountain Resources will also continue to seek quality projects that can be evaluated on their own technical and financial merit. Disclaimer
Star Mountain Resources, Inc. Company Blog
Star Mountain Resources, Inc. News:
Star Mountain Resources Receives Industry Guide 7 Mineral Reserves Report on Balmat Mine
Star Mountain Resources, Inc. Closes Acquisition of Balmat Zinc Mine in New York State
Star Mountain Resources, Inc. to Acquire Balmat Zinc Mine in New York State
Agora Holdings, Inc. (AGHI)
The QualityStocks Daily Newsletter would like to spotlight Agora Holdings, Inc. (AGHI). Today, Agora Holdings, Inc. closed trading at $0.35, up 12.90%, on 623,752 volume with 263 trades. The stock’s average daily volume over the past 60 days is 100,409, and its 52-week low/high is $0.03/$2.50.
Agora Holdings, Inc. (AGHI), together with its wholly-owned subsidiary, Geegle Media, is leading a diversified family entertainment and media enterprise through business segments which include: TV on Demand, interactive media, business products and consumer platforms. With its multi-dimensional approach, Geegle Media supports Agora Holdings' mission to deliver innovate and high-quality business solution products and to deliver video content from around the world.
Geegle Media web platforms include; GeegleTV, Frame, 1000Salads, RealtyTV and LobbyTV. Geegle TV is a multi-platform video entertainment website that curates high-quality video content from around the world. In 2016, GeegleTV will serve as co-producer by airing original content. By exposing undiscovered content to millions of users and rendering it shareable to social media, Geegle TV will serve as a marketing partner to local and internationally based TV shows not yet on the open market.
For commercial use, Geegle Media provides a variety of solutions that include web development and billing software for VoIP applications. RealtyTV is its state-of-the-art platform for real estate brokerages. LobbyTV is another of its widely used products by business offices. For individuals, Geegle TV combines radio, On Demand movies, news, sports and children's content.
Geegle Media is also developing 1000salads, an online hub that encourages healthy lifestyles. The portal will feature recipes and products, health-oriented articles and a curated selection of local restaurants and grocers that deliver to the health-conscious user. Currently in its alpha stage of development, 1000salads is gearing up its sales and marketing in preparation for its launch in 2016.
Geegle Media differs from other On Demand providers, such as Netflix and HBO, in that its service is free of constraints such as subscription, fees and penalties. As consumers increasingly opt for personalized sources of entertainment, Agora recognizes the vast opportunities and growth potential provided by the rising popularity of TV On Demand. The company also benefits from strong and visionary management with a track record of bringing innovative ideas to fruition. Disclaimer
Agora Holdings, Inc. Company Blog
Agora Holdings, Inc. News:
Agora Holdings Inc.'s Geegle Media Set to Release FRAME This Month
Agora Holdings, Inc. (AGHI) CEO Featured in Exclusive QualityStocks Interview
Agora Holdings, Inc. (AGHI) Announces Engagement of QualityStocks Corporate Communications Suite
Oakridge Global Energy Solutions, Inc. (OGES)
The QualityStocks Daily Newsletter would like to spotlight Oakridge Global Energy Solutions, Inc. (OGES). Today, On the Move Systems, Inc. closed trading at $0.65, up 8.33%, on 4,100 volume with 6 trades. The stock’s average daily volume over the past 60 days is 18,816, and its 52-week low/high is $0.20/$2.40.
Oakridge Global Energy Solutions, Inc. (OGES) is an integrated energy storage solutions company focused on the design, development and manufacture of high-quality cells, batteries and power systems. The company's innovative 'Made in the U.S.A.' product line includes multiple lithium-ion technologies and form factors that are optimized to address three high-demand target markets – including stationary and grid storage; motive applications, such as electric and hybrid electric fleet vehicles; and specialty applications, such as military, aerospace, marine, medical and telecom backup.
Through a recent restructuring of its operations, Oakridge strategically positioned itself to expand its market reach moving forward. The company currently owns and operates two manufacturing facilities in Melbourne, Florida, which play an instrumental role in its efforts to meet the growing demand for its cutting-edge large format Pro Series golf car batteries and its small format Patriot Series RC batteries. These operations also allow Oakridge to bring stable employment opportunities back to the U.S., effectively highlighting its tireless commitment to the revitalization of the country's manufacturing industry.
The company also maintains a presence on the international stage through its recently formed subsidiary, Oakridge Global Energy Solutions Limited, Hong Kong. This subsidiary, which is expected to serve as the foundation for Oakridge's sales efforts throughout the Asia-Pacific region, was created primarily to address the tremendous international demand for its revolutionary stored energy solutions. The company also maintains a substantial interest in Leclanche S.A., a Swiss developer and manufacturer of large-sized lithium-ion batteries that was originally founded in 1909.
Oakridge has indicated plans to expand its presence in a collection of markets throughout Europe and Asia as it continues to build upon its established product development and manufacturing infrastructure. The company will lean on the expertise of its proven management team – which includes well over a century of combined industry experience – as it looks to increase its share of the $12 billion domestic battery manufacturing industry. Disclaimer
Oakridge Global Energy Solutions, Inc. Company Blog
Oakridge Global Energy Solutions, Inc. News:
Oakridge Announces New Corporate Image, Branding and Media Communications Tools as it Enters Full-Scale Production for 2016
Oakridge Providing Batteries for Unmanned Maritime Vessels
Oakridge Sells Interest in Leclanche S.A., Releasing Funding for Corporate Growth
Torchlight Energy Resources, Inc. (TRCH)
The QualityStocks Daily Newsletter would like to spotlight Torchlight Energy Resources, Inc. (NASDAQ:TRCH). Today, Torchlight Energy Resources, Inc. closed trading at $0.69, up 6.15%, on 66,810 volume with 178 trades. The stock’s average daily volume over the past 60 days is 105,377, and its 52-week low/high is $0.2201/$2.44.
Torchlight Energy Resources, Inc. (NASDAQ:TRCH) is a high growth oil and gas Exploration and Production (E&P) company primarily focused on the acquisition and development of highly profitable domestic oil fields. Leveraging a diverse portfolio, carefully selected interests, and a strong management team are pillars of Torchlight's broader success strategy.
The company maintains a diversified energy portfolio by holding interests in numerous projects in multiple established plays, and currently holds interests in Texas, Oklahoma and Kansas, where its targets are established plays such as the Wolf Penn, Eagle Ford Shale, Mississippi Limestone and Hunton Limestone trends.
Torchlight is currently moving forward on the next phase of drilling on three new wells in its Orogrande Project in West Texas, where the company owns a 47.5% working interest on 168,000 acres alongside Founders Oil and Gas, LLC. Torchlight drilled the Rich A-11 well (6,091 feet) on the Orogrande Project in March last year and subsequently executed a $50 million JV farm-out agreement with Midland, Texas-based Founders Oil and Gas, who initiated frac work on the well in November.
The Marcelina Creek Project in South Texas, with its prime access to the Austin Chalk, Buda, and Eagle Ford formations, is surrounded on all four sides by leading Eagle Ford producers. Torchlight's Johnson #4 well was recently re-entered and drilled laterally to approximately 2500 feet in the Austin Chalk Formation. With more than 20 additional drilling locations on its Marcelina Creek Asset, the project has the potential to positively impact cash flows and production sustainability.
Torchlight's executive team and board of directors are led by CEO John Brda and COO Willard McAndrew III. Combined they have over 50 years of experience in the oil and gas industry as executives, investors and consultants to the industry. Their knowledge base includes all aspects of the business including: operations, mid stream, capital formation, purchase and sale of assets, re-entries, investor relations and oil and gas consulting for public and private companies. Disclaimer
Torchlight Energy Resources, Inc. Company Blog
Torchlight Energy Resources, Inc. News:
Torchlight Energy Provides Update on the Orogrande Project
Year-End Review 2015: Torchlight Energy (NASDAQ: TRCH) by StockNewsNow
Torchlight Energy Announces Success on Its Johnson #4 Re-Entry
Today's Top 3
The QualityStocks Public Company Sponsor News
- Get profiles for new featured companies at clients.qualitystocks.net
- Agora Holdings, Inc. (AGHI) CEO Featured in Exclusive QualityStocks Interview
- Alternet Systems (ALYI) Announces Caprock Research Report with Near Term Price Target of $0.05 and 'Accumulate' Recommendation
- Avant Diagnostics, Inc. (AVDX) Amarantus Enters into Letter of Intent to Merge Diagnostics Business Unit into Avant Diagnostics
- Cherubim Interests, Inc. (CHIT) Signs MOU to Acquire Revenue-Producing Company
- Dominovas Energy Corp. (DNRG) U.S. Securities and Exchange Commission Approves Dominovas Energy's S-1 Registration
- FlexWeek, Inc. (FXWK) Announces Engagement of QualityStocks Corporate Communications Suite
- Giggles N' Hugs, Inc. (GIGL) CEO Discusses 2016 Growth Strategies in Second QualityStocks Interview
- GTX Corp. (GTXO) to Present at 2nd Annual Innovations Investor Conference and Announces Date of Shareholder Meeting
- International Stem Cell Corp. (ISCO) Signed a Clinical Service Agreement With the Florey Institute of Neuroscience and Mental Health
- Lingo Media Corp. (LMDCF) to Present at the World Outlook Financial Conference 2016 on January 29th & 30th
- Moxian, Inc. (MOXC) Enters Into Exclusive Agreement and Development Partnership With Xinhua Media Affiliate
- Nutra Pharma Corp. (NPHC) 7-year Marketing Exclusivity for Pediatric MS RPI-78M is more than just Luck
- Oakridge Global Energy Solutions, Inc. (OGES) Providing Batteries for Unmanned Maritime Vessels
- OurPet's Company (OPCO) Commits to Further Innovation in Pet Products That Enhance Pet/Owner Relationship
- Star Mountain Resources Inc. (SMRS) Receives Industry Guide 7 Mineral Reserves Report on Balmat Mine
- Torchlight Energy Resources, Inc. (TRCH) Provides Update on the Orogrande Project
- View Systems, Inc. (VSYM) to Acquire Y.M. Advantage, Inc.